Aduro Biotech (Aduro Biotech) EBITDA Margin % : -250.72% (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aduro Biotech's EBITDA for the three months ended in Jun. 2020 was $-13.98 Mil. Aduro Biotech's Revenue for the three months ended in Jun. 2020 was $5.57 Mil. Therefore, Aduro Biotech's EBITDA margin for the quarter that ended in Jun. 2020 was -250.72%.

Aduro Biotech EBITDA Margin % Historical Data

The historical data trend for Aduro Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech EBITDA Margin % Chart

Aduro Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EBITDA Margin %

Get a 7-Day Free Trial

-17.60

-136.76

-594.40

-612.55

-465.14

Aduro Biotech Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
EBITDA Margin %	Get a 7-Day Free Trial															-378.76	-381.52	-533.91	-62.39	-250.72

Competitive Comparison of Aduro Biotech's EBITDA Margin %

For the Biotechnology subindustry, Aduro Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aduro Biotech's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aduro Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aduro Biotech's EBITDA Margin % falls into.

Aduro Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aduro Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2019 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2019 )	/	Revenue (A: Dec. 2019 )
	=	-80.273	/	17.258
	=	-465.14 %

Aduro Biotech's EBITDA Margin % for the quarter that ended in Jun. 2020 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2020 )	/	Revenue (Q: Jun. 2020 )
	=	-13.975	/	5.574
	=	-250.72 %

Aduro Biotech (NAS:ADRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aduro Biotech EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aduro Biotech (Aduro Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 Heinz Avenue, Berkeley, CA, USA, 94710

Website

https://www.aduro.com

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.

Executives

Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat	director	C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber	officer: SVP, GC and Secretary	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman	officer: Chief Legal Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710